Sign in to add mentor
Edward Ervin Smissman grad student 1967 University of Kansas
 (Part I : a chemical approach to schizophrenia : Part II : azodicarboxylic acid esters as dealkylating agents : a mechanistic study.)
Henry Rapoport post-doc 1967-1969 UC Berkeley
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Malamas MS, Lamani M, Farah SI, et al. (2021) Design and Synthesis of Highly Potent and Specific ABHD6 Inhibitors. Chemmedchem
Ho TC, Tius MA, Nikas SP, et al. (2021) Oxa-Adamantyl Cannabinoids. Bioorganic & Medicinal Chemistry Letters. 127882
Kokona D, Spyridakos D, Tzatzarakis M, et al. (2021) The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity. Neuropharmacology. 185: 108450
Wooldridge LM, Ji L, Liu Y, et al. (2020) Antiemetic Effects of Cannabinoid Agonists in Nonhuman Primates. The Journal of Pharmacology and Experimental Therapeutics
Hua T, Li X, Wu L, et al. (2020) Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-G Complex Structures. Cell
Malamas MS, Farah SI, Lamani M, et al. (2019) Design and synthesis of cyanamides as potent and selective N-acylethanolamine acid amidase inhibitors. Bioorganic & Medicinal Chemistry. 115195
Kangas BD, Zakarian AS, Vemuri K, et al. (2019) Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates. The Journal of Pharmacology and Experimental Therapeutics
Lamani M, Malamas MS, Farah SI, et al. (2019) Piperidine and piperazine inhibitors of fatty acid amide hydrolase targeting excitotoxic pathology. Bioorganic & Medicinal Chemistry. 115096
Alapafuja SO, Nikas SP, Ho TC, et al. (2019) Chain Substituted Cannabilactones with Selectivity for the CB2 Cannabinoid Receptor. Molecules (Basel, Switzerland). 24
Salaga M, Binienda A, Tichkule RB, et al. (2019) Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. J. Pharmacol. (2018), 836 34-43]. European Journal of Pharmacology. 172656
See more...